Trastuzumab deruxtecan for previously treated HER2-positive metastatic breast cancer

Published on 17 Jul 2023
Last Updated on 01 Sep 2023

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended trastuzumab deruxtecan (T-DXd) for inclusion on the MOH List of Subsidised Drugs for treating human epidermal growth factor receptor 2 (HER2)-positive unresectable or metastatic breast cancer after a prior anti-HER2-based regimen. The decision was based on the uncertain extent of clinical benefit and unfavourable cost-effectiveness of T-DXd at the price proposed by the company compared with alternative treatments.

Clinical indication, subsidy class and MediShield Life claim limit for T-DXd are provided in the Annex.

Trastuzumab deruxtecan for previously treated HER2-positive metastatic breast cancer (Updated 1 Sep 23) [PDF, 246 KB]

PES Trastuzumab deruxtecan for previously treated HER2-positive metastatic breast cancer (Updated 1 Sep 23) [PDF, 122 KB]